Form 4: Treace Medical Concepts Executive Reports Stock Transaction
Insider Transaction (Form 4)
Sean F. Scanlan, Chief Innovation Officer of Treace Medical Concepts, Inc., reported a transaction in 207 shares of common stock on October 24, 2026.
Summary
- Tax/exercise-price withholding: disposed of 207 Common Stock on October 24, 2026; holds 634,656 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Sean F. Scanlan — Officer (Chief Innovation Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-24 | Tax/exercise-price withholding | Common Stock | 207 | — | — | 634,656 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-24 | Tax/exercise-price withholding (207 shares) |
Keywords
insider transaction, Form 4, TMCI, TREACE MEDICAL CONCEPTS, INC., neutral, Sean F. Scanlan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.